Nootropic profile
Bifemelane
A multi-target nootropic marketed in Japan (as Celeport/Alnert) that enhances cholinergic and monoaminergic neurotransmission, prescribed for cerebrovascular dementia and cognitive impairment.
Best for
Educational only: this is not medical advice. Always check with a qualified healthcare professional before starting any supplement.
What is Bifemelane?
Bifemelane (marketed as Alnert and Celeport in Japan) is a nootropic and neuroprotective drug that has been available in Japanese clinical practice since the mid-1980s.
What it does for you
Community and editorial ratings, out of 5:
How to take it
- Standard clinical dose: 150 mg taken twice daily (300 mg total daily dose) as prescribed in Japanese clinical practice
- Starting dose: 150 mg once daily, increasing to 150 mg twice daily after 1-2 weeks based on tolerability
- Dose range: 150-300 mg daily, with most clinical trials using the 300 mg daily dose (150 mg morning and evening)
- Administration: Oral tablets taken after meals; morning and evening dosing is recommended to maintain stable plasma levels throughout the day
- Duration of treatment: Long-term use is common in Japanese clinical practice for chronic cognitive impairment, with treatment courses of 3-12 months...
Watch out for
- Generally well-tolerated: Decades of clinical use in Japan have established a favourable safety profile, with most adverse effects being mild and manageable
- Common side effects: Nausea, abdominal discomfort, diarrhoea, rash, and headache are the most frequently reported adverse effects in clinical trials and...
- Hepatotoxicity reports: Rare cases of liver function abnormalities have been reported; periodic monitoring of liver function tests is recommended during...
- MAO inhibitor interactions: Although Bifemelane's MAO inhibition is relatively mild, caution is warranted with concurrent use of other MAO inhibitors,...
- Blood pressure monitoring: The combination of MAO inhibition and noradrenergic enhancement warrants monitoring for hypertensive episodes, particularly in...
The science, if you're curious.
- Reversibly inhibits both MAO-A and MAO-B enzymes, reducing the degradation of dopamine, norepinephrine, serotonin, and other monoamine neurotransmitters,...
- Promotes the release of acetylcholine from cholinergic nerve terminals in the cortex and hippocampus, supporting memory encoding, attention, and cognitive...
- Through MAO-B inhibition and possible direct mechanisms, increases dopamine levels in the prefrontal cortex and striatum, supporting executive function,...
- Increases regional cerebral blood flow, particularly in ischaemic areas, improving oxygen and glucose delivery to metabolically compromised brain tissue
Where to find it
- Kawamura et al. (1988): Clinical trial of Bifemelane in patients with cerebrovascular dementia demonstrating cognitive and functional improvements, published in Japanese Clinical Pharmacology and Therapeutics
- Otomo et al. (1991): Multi-centre double-blind study of Bifemelane in dementia patients, published in the Japanese Journal of Clinical Pharmacology and Therapeutics
- Nishibe et al. (1987): Pharmacological study demonstrating Bifemelane's effects on cerebral blood flow and glucose metabolism in the Japanese Journal of Pharmacology
- Japanese PMDA product information: Official prescribing information for Alnert (Bifemelane) tablets as approved by the Japanese Pharmaceuticals and Medical Devices Agency
- Nagatsu and Yoshida (1988): Review of Bifemelane's monoamine oxidase inhibitory activity and neuroprotective mechanisms in Neuroscience Letters
Frequently asked
A multi-target nootropic marketed in Japan (as Celeport/Alnert) that enhances cholinergic and monoaminergic neurotransmission, prescribed for cerebrovascular dementia and cognitive impairment.
The main benefits people report from Bifemelane are: Cognitive Enhancement, Energy, Focus, Memory, Mood, Motivation.
Standard clinical dose: 150 mg taken twice daily (300 mg total daily dose) as prescribed in Japanese clinical practiceStarting dose: 150 mg once daily, increasing to 150 mg twice daily after 1-2 weeks based on tolerabilityDose range: 150-300 mg daily, with most clinical trials using the 300 mg daily...
Generally well-tolerated: Decades of clinical use in Japan have established a favourable safety profile, with most adverse effects being mild and manageableCommon side effects: Nausea, abdominal discomfort, diarrhoea, rash, and headache are the most frequently reported adverse effects in clinical tr...
Reversibly inhibits both MAO-A and MAO-B enzymes, reducing the degradation of dopamine, norepinephrine, serotonin, and other monoamine neurotransmitters,...Promotes the release of acetylcholine from cholinergic nerve terminals in the cortex and hippocampus, supporting memory encoding, attention, and...
Rate Bifemelane
Log in to leave an overall rating.
What people are saying
Log in to leave a comment.
No comments yet. Be the first to share your experience.